Eileanoir B Johnson
Overview
Explore the profile of Eileanoir B Johnson including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
29
Citations
443
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Papoutsi M, Flower M, Hensman Moss D, Holmans P, Estevez-Fraga C, Johnson E, et al.
Brain Commun
. 2022 Dec;
4(6):fcac279.
PMID: 36519153
An important step towards the development of treatments for cognitive impairment in ageing and neurodegenerative diseases is to identify genetic and environmental modifiers of cognitive function and understand the mechanism...
2.
Lowe A, Rodrigues F, Arridge M, De Vita E, Johnson E, Scahill R, et al.
Brain Commun
. 2022 Nov;
4(6):fcac258.
PMID: 36382217
Proton magnetic resonance spectroscopy is a non-invasive method of exploring cerebral metabolism. In Huntington's disease, altered proton magnetic resonance spectroscopy-determined concentrations of several metabolites have been described; however, findings are...
3.
McColgan P, Gregory S, Zeun P, Zarkali A, Johnson E, Parker C, et al.
Brain
. 2022 Jun;
145(11):3953-3967.
PMID: 35758263
Upregulation of functional network connectivity in the presence of structural degeneration is seen in the premanifest stages of Huntington's disease (preHD) 10-15 years from clinical diagnosis. However, whether widespread network...
4.
Zeun P, McColgan P, Dhollander T, Gregory S, Johnson E, Papoutsi M, et al.
Neuroimage Clin
. 2022 Jan;
33:102927.
PMID: 34999565
Objectives: To investigate the timeframe prior to symptom onset when cortico-basal ganglia white matter (white matter) loss begins in premanifest Huntington's disease (preHD), and which striatal and thalamic sub-region white...
5.
Wijeratne P, Garbarino S, Gregory S, Johnson E, Scahill R, Paulsen J, et al.
Neurol Genet
. 2021 Oct;
7(5):e617.
PMID: 34660889
Background And Objectives: Longitudinal measurements of brain atrophy using structural MRI (sMRI) can provide powerful markers for tracking disease progression in neurodegenerative diseases. In this study, we use a disease...
6.
Wijeratne P, Johnson E, Gregory S, Georgiou-Karistianis N, Paulsen J, Scahill R, et al.
Front Big Data
. 2021 Aug;
4:662200.
PMID: 34423286
Understanding the order and progression of change in biomarkers of neurodegeneration is essential to detect the effects of pharmacological interventions on these biomarkers. In Huntington's disease (HD), motor, cognitive and...
7.
Validating Automated Segmentation Tools in the Assessment of Caudate Atrophy in Huntington's Disease
Mansoor N, Vanniyasingam T, Malone I, Hobbs N, Rees E, Durr A, et al.
Front Neurol
. 2021 May;
12:616272.
PMID: 33935934
Neuroimaging shows considerable promise in generating sensitive and objective outcome measures for therapeutic trials across a range of neurodegenerative conditions. For volumetric measures the current gold standard is manual delineation,...
8.
Rodrigues F, Byrne L, Lowe A, Tortelli R, Heins M, Flik G, et al.
J Neurochem
. 2021 Apr;
158(2):539-553.
PMID: 33797782
Converging lines of evidence from several models, and post-mortem human brain tissue studies, support the involvement of the kynurenine pathway (KP) in Huntington's disease (HD) pathogenesis. Quantifying KP metabolites in...
9.
Nair A, Johnson E, Gregory S, Osborne-Crowley K, Zeun P, Scahill R, et al.
Biol Psychiatry Cogn Neurosci Neuroimaging
. 2021 Apr;
6(9):910-918.
PMID: 33795209
Background: In this study, we asked whether differences in striatal activity during a reinforcement learning (RL) task with gain and loss domains could be one of the earliest functional imaging...
10.
Johnson E, Parker C, Scahill R, Gregory S, Papoutsi M, Zeun P, et al.
EBioMedicine
. 2021 Mar;
65:103266.
PMID: 33706250
Background: Pathological processes in Huntington's disease (HD) begin many years prior to symptom onset. Recently we demonstrated that in a premanifest cohort approximately 24 years from predicted disease onset, despite...